Targeting BRAFV600E in the treatment of CRC

View/ Open
Date
2023-10Publisher
Brac UniversityAuthor
Roja, Mashwiyat SamrinMetadata
Show full item recordAbstract
The increasing prevalence of BRAFV600E mutated cancers has led to the search and
development of targeted therapies against BRAF mutation. Multiple cancers, including
colorectal cancer (CRC), have been linked to this mutation. While the currently available CRC
drugs have shown initial promise, long-term use of these drugs could lead to the emergence of
resistant CRC cells; therefore, drug repurposing provides a powerful strategy to increase the
existing drug pool. This docking-based study’s aim was to find the possible compounds that
could inhibit the BRAF protein and treat BRAFV600E mutated CRC. Three classes of drugs antihypertensive,
anti-cholesterol and anti-diabetic drugs were explored. Molecular docking,
followed by superimposition, analyzing protein-ligand interactions and comparison of their
pharmacokinetic properties were done. The anti-hypertensive drug, Verapamil showed
promising results as it demonstrated good binding affinity and interaction with the target
protein. However, further in vitro studies and biological assays should be performed to
elucidate Verapamil’s efficacy.